Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if used to treat acute asthma attacks, calling it the first major advance for this aspect of the disease in 50 ...

Patients with eosinophilic granulomatosis with polyangiitis experienced significant improvements in a variety of outcomes with mepolizumab at 12 months, according to a study published in Annals of ...

The antibody drug benralizumab is on the fast track to becoming the first new treatment for certain kinds of asthma and COPD flare-ups seen in 50 years, following promising clinical trial data.

for an additional indication. Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...

The directive outlines a strict phased implementation affecting take-home rations distribution, child attendance tracking, and beneficiary registration through the Poshan Tracker application.

The severe asthma treatment market is experiencing robust expansion, driven by rising disease prevalence, improved diagnostic approaches, and breakthrough therapeutic developments from key ...

Stock Market Today | Share Market Highlights - Find here all the highlights related to Sensex, Nifty, BSE, NSE, share prices and Indian stock markets for 30 May 2025.

DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Beneficient,” “Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary ...

Allergen immunotherapy with omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, and tezepelumab has shown promising outcomes in preventing asthma exacerbations.

AstraZeneca's first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation suitable for administration by patients themselves.